We are thrilled to announce that Biocytogen will attend the World Bispecific Summit Europe from July 8th - 9th in London, UK. As the field is rapidly advancing, the focus is shifting toward more sophisticated antibody designs that enhance both efficacy and safety. Come visit us at Booth #4 to learn how our extensive line of animal models and systematic bioassays can advance your research.
What is the World Bispecific Summit Europe
The World Bispecific Summit Europe is a leading industry forum bringing together senior leaders to discuss the latest advances in bispecific and multispecific antibody therapeutics. Attendees will gain new insights on the next generation of T-cell engagers and bispecific ADCs through technical discussions and in-depth case studies.
Event Overview
Date: July 8th - 9th, 2026
Venue: Novotel London West, 1 Shortlands Hammersmith International Ctre, London W6 8DR, UK
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com
